OCC: Respiratory Virus Panel Nucleic Acid Assay System
What it covers
A respiratory viral panel multiplex nucleic acid assay is a qualitative in vitro diagnostic device intended to simultaneously detect and identify multiple viral nucleic acids extracted from human respiratory specimens or viral culture. The detection and identification of a specific viral nucleic acid from individuals exhibiting signs and symptoms of respiratory infection aids in the diagnosis of respiratory viral infection when used in conjunction with other clinical and laboratory findings. The device is intended for detection and identification of a combination of the following viruses: Influenza A and Influenza B, Influenza A subtype H1 and Influenza A subtype H3, Respiratory Syncytial Virus subtype A and Respiratory Syncytial Virus subtype B, Parainfluenza 1, Parainfluenza 2, and Parainfluenza 3 virus, Human Metapneumovirus, Rhinovirus, and Adenovirus.
FDA’s definition of product code OCC, from the Product Classification database.
Recent clearances
| 510(k) | Device | Applicant | Decision | Type |
|---|---|---|---|---|
| K262747 | ID NOW Influenza A & B 2; ID NOW RSV; ID NOW Strep A 2; ID NOW COVID-19 2.0 | Abbott Diagnostics Scarborough, Inc. | Aug 31, 2026 | Special |
| K254139 | BioCode® Respiratory Pathogen Panel (RPP) | Applied BioCode, Inc. | May 1, 2026 | Traditional |
| K242613 | NxTAG® Respiratory Pathogen Panel | Luminex Molecular Diagnostics, Inc. | Oct 2, 2024 | Special |
| K232775 | ID NOW Influenza A & B 2 | Abbott Diagnostics Scarborough, Inc. | Oct 10, 2023 | Special |
| K231017 | Panther Fusion AdV/hMPV/RV Assay | Hologic, Inc. | May 5, 2023 | Special |
| K213822 | cobas Influenza A/B & RSV nucleic acid test for use on the cobas Liat System | Roche Molecular Systems, Inc. | Jul 6, 2022 | Special |
| K210234 | cobas Influenza A/B & RSV Nucleic acid test for use on the cobas Liat System | Roche Molecular Systems, Inc. | Feb 16, 2021 | Special |
| K201505 | Simplexa Flu A/B & RSV Direct Gen II, Simplexa Flu A/B & RSV Positive Control Pack | Diasorin Molecular, LLC | Aug 22, 2020 | Traditional |
| K200065 | cobas Influenza A/B Nucleic acid test for use on the cobas Liat System, cobas Influenza A/B & RSV Nucleic acid test for use on the cobas Liat System, cobas Strep A Nucleic acid test for use on the cobas Liat System | Roche Molecular Systems, Inc. | Feb 10, 2020 | Special |
| K192485 | BioCode Respiratory Pathogen Panel (RPP) | Applied BioCode, Inc. | Dec 23, 2019 | Traditional |
Clearances by year
68 OCC 510(k)s were cleared from 2011 to Oct 29, 2026. Days to decision run from the day FDA received the 510(k) to its decision, including time on hold.
| Year | Clearances | Median days to decision |
|---|---|---|
| 2026 (so far) | 2 | 79 |
| 2024 | 1 | 29 |
| 2023 | 2 | 27 |
| 2022 | 1 | 210 |
| 2021 | 1 | 19 |
| 2020 | 2 | 53 |
| 2019 | 5 | 31 |
| 2018 | 4 | 134 |
| 2017 | 10 | 136 |
| 2016 | 7 | 92 |
| 2015 | 8 | 85 |
| 2014 | 4 | 94 |
| 2013 | 6 | 79 |
| 2012 | 6 | 125 |
| 2011 | 9 | 82 |
Who submits
29 applicants cleared a OCC device since 2011. 87% of the clearances went to applicants in United States, then Canada (9%), Belgium (1%) and Germany (1%). By type: Traditional 63%, Special 28% and Dual Track 9%.
| Applicant | Clearances since 2011 |
|---|---|
| Cepheid | 8 |
| Luminex Molecular Diagnostics, Inc. | 6 |
| Alere Scarborough, Inc. | 5 |
| Biofire Diagnostics, LLC | 4 |
| Hologic, Inc. | 4 |
| Roche Molecular Systems, Inc. | 4 |
| Abbott Diagnostics Scarborough, Inc. | 3 |
| Gen-Probe Prodesse, Inc. | 3 |
How FDA classifies it
Class II (special controls). The special controls are:
(1) FDA's guidance document entitled “Class II Special Controls Guidance Document: Respiratory Viral Panel Multiplex Nucleic Acid Assay;”
(2) For a device that detects and identifies Human Metapneumovirus, FDA's guidance document entitled “Class II Special Controls Guidance Document: Testing for Human Metapneumovirus (hMPV) Using Nucleic Acid Assays;” and
(3) For a device that detects and differentiates Influenza A subtype H1 and subtype H3, FDA's guidance document entitled “Class II Special Controls Guidance Document: Testing for Detection and Differentiation of Influenza A Virus Subtypes Using Multiplex Nucleic Acid Assays.” See § 866.1(e) for the availability of these guidance documents.
From 21 CFR 866.3980. Special controls are the requirements a 510(k) must show it meets.
Standards
21 CFR 866.3980 names no consensus standards. Check FDA’s recognized standards database, or ask which standards recent OCC clearances declared.
Ask about OCC
Questions about OCC
What is FDA product code OCC?
Product code OCC, “Respiratory Virus Panel Nucleic Acid Assay System” in FDA's classification database, is a Class II device type under 21 CFR 866.3980 (respiratory viral panel multiplex nucleic acid assay), reviewed by FDA's Microbiology panel. FDA's 510(k) database lists 80 clearances under OCC, 68 of them since 2011.
How many 510(k) clearances are there under OCC?
FDA’s 510(k) database listed 80 clearances under OCC as of Oct 29, 2026, 68 of them decided since 2011; the most recent decision was Aug 31, 2026. The Predicate Finder searches the live database.
How long does FDA take to clear a OCC 510(k)?
For the 2 OCC clearances decided in the two years before Oct 29, 2026, the median time from FDA receiving the 510(k) to its decision was 79 days. That counts calendar days, including time the submission was on hold waiting for answers from the submitter.
Which companies have the most OCC clearances?
Since 2011: Cepheid (8), Luminex Molecular Diagnostics, Inc. (6), Alere Scarborough, Inc. (5), Biofire Diagnostics, LLC (4) and Hologic, Inc. (4). 29 applicants have cleared a OCC device in that time.